Spots Global Cancer Trial Database for placebo administration
Every month we try and update this database with for placebo administration cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase II Study of Isoflavone G-2535 (Genistein) in Patients With Bladder Cancer | NCT00118040 | Recurrent Bladd... Stage I Bladder... Stage II Bladde... Stage III Bladd... | Genistein Laboratory Biom... Pharmacological... Placebo Adminis... Therapeutic Con... | 18 Years - | National Cancer Institute (NCI) | |
| Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma | NCT04201873 | Recurrent Gliob... | Dendritic Cell ... Pembrolizumab Placebo Adminis... Poly ICLC | 18 Years - | Jonsson Comprehensive Cancer Center | |
| To Evaluate if Green Tea Can be Effective in Reducing the Progression of Prostate Cancer in Men on Close Monitoring | NCT04597359 | Prostate Carcin... | Placebo Adminis... Quality-of-Life... Questionnaire A... Sinecatechins | 21 Years - | Eastern Cooperative Oncology Group | |
| CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant | NCT06059391 | Acute Lymphobla... Acute Myeloid L... Chronic Lymphoc... Chronic Myeloid... Hematopoietic a... Hodgkin Lymphom... Myelodysplastic... Myelofibrosis Myeloproliferat... Non-Hodgkin Lym... | Allogeneic Hema... Biospecimen Col... Granulocyte Col... Hematopoietic C... Multi-peptide C... Pheresis Placebo Adminis... Stem Cell Mobil... | 18 Years - | City of Hope Medical Center | |
| Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Patients With Advanced Cancer | NCT05403580 | Advanced Malign... Hematopoietic a... | Olanzapine Placebo Adminis... Questionnaire A... | 18 Years - | Mayo Clinic | |
| Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant | NCT00114101 | DS Stage I Mult... DS Stage II Mul... DS Stage III Mu... Refractory Mult... Smoldering Mult... | Autologous Hema... Laboratory Biom... Lenalidomide Melphalan Peripheral Bloo... Placebo Adminis... | 18 Years - 70 Years | National Cancer Institute (NCI) | |
| Metformin for the Prevention of Oral Cancer in Patients With Oral Leukoplakia or Erythroplakia | NCT05237960 | Erythroplakia Oral Leukoplaki... | Biopsy Biospecimen Col... Extended Releas... Placebo Adminis... | 21 Years - | University of Arizona | |
| Alteplase Through an Indwelling Pleural Catheter for the Management of Symptomatic Septated Malignant Pleural Effusion | NCT06184321 | Hematopoietic a... Malignant Solid... | Alteplase Placebo Adminis... | 18 Years - | M.D. Anderson Cancer Center | |
| Dolcanatide in Preventing Colorectal Cancer in Healthy Volunteers | NCT03300570 | Colorectal Carc... | Dolcanatide Laboratory Biom... Placebo Adminis... Questionnaire A... | 18 Years - 65 Years | National Cancer Institute (NCI) | |
| Metformin in High Responder Polycystic Ovary Syndrome (PCOS) Patients Undergoing IVF Cycles | NCT01233206 | Infertility Polycystic Ovar... | Metformin Placebo adminis... | 18 Years - 35 Years | University Magna Graecia | |
| Phase II Study of Isoflavone G-2535 (Genistein) in Patients With Bladder Cancer | NCT00118040 | Recurrent Bladd... Stage I Bladder... Stage II Bladde... Stage III Bladd... | Genistein Laboratory Biom... Pharmacological... Placebo Adminis... Therapeutic Con... | 18 Years - | National Cancer Institute (NCI) | |
| Berberine Chloride in Preventing Colorectal Cancer in Patients With Ulcerative Colitis in Remission | NCT02365480 | Ulcerative Coli... | Berberine Chlor... Laboratory Biom... Placebo Adminis... | 18 Years - 70 Years | National Cancer Institute (NCI) | |
| Lactobacillus Plantarum in Preventing Acute Graft Versus Host Disease in Children Undergoing Donor Stem Cell Transplant | NCT03057054 | Hematopoietic a... Leukemia Lymphoma | Allogeneic Hema... Lactobacillus p... Lactobacillus p... Placebo Adminis... | 2 Years - 25 Years | Children's Oncology Group | |
| Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer | NCT02393690 | Metastatic Thyr... Poorly Differen... Recurrent Thyro... Stage IV Thyroi... Stage IV Thyroi... Stage IVA Thyro... Stage IVA Thyro... Stage IVB Thyro... Stage IVB Thyro... Stage IVC Thyro... Stage IVC Thyro... | Iodine I-131 Placebo Adminis... Selumetinib | 18 Years - | Academic and Community Cancer Research United | |
| Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer | NCT03199885 | Metastatic Brea... Metastatic HER2... Recurrent Breas... Recurrent HER2-... Stage III Breas... Stage IV Breast... Unresectable Br... Unresectable HE... | Atezolizumab Biopsy Bone Scan Computed Tomogr... Docetaxel Magnetic Resona... Paclitaxel Pertuzumab Placebo Adminis... Quality-of-Life... Trastuzumab | 18 Years - | National Cancer Institute (NCI) | |
| Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO Trial | NCT06022822 | Prostate Adenoc... | Biopsy Biospecimen Col... Placebo Adminis... Urolithin A Sup... | 18 Years - | National Cancer Institute (NCI) | |
| CD24Fc for the Treatment of Immune Related Adverse Events in Patients With Advanced Solid Tumors, TIRAEC Study | NCT04552704 | Advanced Malign... | CD24 Extracellu... Placebo Adminis... | 18 Years - | University of California, Davis | |
| Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) | NCT02194738 | Stage IB Lung N... Stage II Lung N... Stage IIA Lung ... Stage IIB Lung ... Stage IIIA Lung... Stage IIIA Lung... Stage IIIB Lung... | Biospecimen Col... Carboplatin Cisplatin Clinical Observ... Computed Tomogr... Crizotinib Cytology Specim... Echocardiograph... Erlotinib Gemcitabine Hyd... Nivolumab Paclitaxel Pembrolizumab Pemetrexed Pemetrexed Diso... Placebo Adminis... Positron Emissi... | 18 Years - | National Cancer Institute (NCI) | |
| Gemcitabine Hydrochloride With or Without WEE1 Inhibitor MK-1775 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer | NCT02101775 | Ovarian Brenner... Ovarian Carcino... Ovarian Clear C... Ovarian Endomet... Ovarian Mucinou... Ovarian Seromuc... Ovarian Serous ... Ovarian Serous ... Ovarian Undiffe... Recurrent Fallo... Recurrent Ovari... Recurrent Prima... | Adavosertib Gemcitabine Hyd... Laboratory Biom... Pharmacological... Placebo Adminis... Questionnaire A... | 18 Years - | National Cancer Institute (NCI) | |
| Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors | NCT01609790 | Giant Cell Glio... Glioblastoma Gliosarcoma Oligodendroglio... Recurrent Brain... Recurrent Gliob... | Bevacizumab Laboratory Biom... Pharmacological... Placebo Adminis... Trebananib | 18 Years - | National Cancer Institute (NCI) | |
| Effect of Opioid Infusion Rate on Abuse Liability Potential of Intravenous Hydromorphone for Cancer Pain | NCT04296305 | Hematopoietic a... Malignant Solid... | Hydromorphone Placebo Adminis... Questionnaire A... | 18 Years - | M.D. Anderson Cancer Center | |
| Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid Tumors | NCT01841736 | Foregut Neuroen... Hindgut Neuroen... Metastatic Dige... Metastatic Neur... Midgut Neuroend... Neuroendocrine ... Recurrent Diges... Regional Digest... | Biospecimen Col... Computed Tomogr... Echocardiograph... Laboratory Biom... Magnetic Resona... Multigated Acqu... Pazopanib Hydro... Placebo Adminis... Quality-of-Life... X-Ray Imaging | 18 Years - | National Cancer Institute (NCI) | |
| Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma | NCT04527549 | Clinical Stage ... Locally Advance... Pathologic Stag... Pathologic Stag... Unresectable Me... | Dabrafenib Mesy... Hydroxychloroqu... Placebo Adminis... Trametinib Dime... | 18 Years - | Eastern Cooperative Oncology Group | |
| Dolcanatide in Preventing Colorectal Cancer in Healthy Volunteers | NCT03300570 | Colorectal Carc... | Dolcanatide Laboratory Biom... Placebo Adminis... Questionnaire A... | 18 Years - 65 Years | National Cancer Institute (NCI) | |
| Open Labeled Placebo in Reducing Cancer Related Fatigue in Patients With Advanced Cancer | NCT03927885 | Advanced Malign... Metastatic Mali... Recurrent Malig... | Placebo Adminis... Quality-of-Life... Questionnaire A... Waiting List | 18 Years - | M.D. Anderson Cancer Center | |
| Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Patients With Advanced Cancer | NCT05403580 | Advanced Malign... Hematopoietic a... | Olanzapine Placebo Adminis... Questionnaire A... | 18 Years - | Mayo Clinic | |
| EMLA Topical Cream for Treatment of Pain in Patients Receiving Intra-Dermal Technetium 99 Injections for Lymphoscintigraphy for Skin Cancers | NCT06223659 | Cutaneous Melan... Merkel Cell Car... Skin Squamous C... | Eutectic Mixtur... Placebo Adminis... Questionnaire A... | 18 Years - 99 Years | Ohio State University Comprehensive Cancer Center | |
| PEA for the Relief of Chemotherapy-Induced Peripheral Neuropathy | NCT05246670 | Chemotherapy-In... Hematopoietic a... Malignant Solid... | Palmidrol Placebo Adminis... Quality-of-Life... | 18 Years - | Academic and Community Cancer Research United | |
| Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib Malate in Treating Patients With Extensive-Stage Small Cell Lung Cancer | NCT00453154 | Extensive Stage... Recurrent Lung ... | Carboplatin Cisplatin Etoposide Laboratory Biom... Placebo Adminis... Sunitinib Malat... | 18 Years - | National Cancer Institute (NCI) | |
| Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast Cancer | NCT02598557 | Stage 0 Breast ... Stage I Breast ... Stage IA Breast... Stage IB Breast... Stage II Breast... Stage IIA Breas... Stage IIB Breas... | Exemestane Laboratory Biom... Pharmacological... Placebo Adminis... Quality-of-Life... Questionnaire A... Therapeutic Con... | - 75 Years | National Cancer Institute (NCI) | |
| Leflunomide for the Treatment of Severe COVID-19 in Patients With a Concurrent Malignancy | NCT04532372 | Hematopoietic a... Malignant Solid... Symptomatic COV... | Best Practice Leflunomide Placebo Adminis... | 18 Years - | City of Hope Medical Center | |
| Ascorbic Acid and Chemotherapy for the Treatment of Relapsed or Refractory Lymphoma, CCUS, and Chronic Myelomonocytic Leukemia | NCT03418038 | Clonal Cytopeni... High Grade B-Ce... Recurrent Diffu... Recurrent Hodgk... Recurrent Lymph... Refractory Diff... Refractory Lymp... Chronic Myelomo... | Ascorbic Acid Carboplatin Cisplatin Cytarabine Dexamethasone Etoposide Gemcitabine Hyd... Ifosfamide Laboratory Biom... Oxaliplatin Placebo Adminis... Questionnaire A... Rituximab Decitabine Biospecimen Col... Core Biopsy Bone Marrow Asp... Bone Marrow Bio... Echocardiograph... Positron Emissi... Magnetic Resona... Central Venous ... Portacath Place... Computed Tomogr... | 18 Years - | Mayo Clinic | |
| Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced and Incurable Solid Tumors | NCT05705492 | Advanced Malign... | Biospecimen Col... Computed Tomogr... Olanzapine Placebo Adminis... Questionnaire A... | 18 Years - | OHSU Knight Cancer Institute | |
| Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant | NCT00114101 | DS Stage I Mult... DS Stage II Mul... DS Stage III Mu... Refractory Mult... Smoldering Mult... | Autologous Hema... Laboratory Biom... Lenalidomide Melphalan Peripheral Bloo... Placebo Adminis... | 18 Years - 70 Years | National Cancer Institute (NCI) | |
| Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases | NCT02595905 | Metastatic BRCA... Metastatic Brea... Metastatic Mali... Metastatic Trip... Recurrent Breas... Stage IV Breast... | Cisplatin Laboratory Biom... Placebo Adminis... Veliparib | 18 Years - | National Cancer Institute (NCI) | |
| Aspirin in Preventing Disease Recurrence in Patients With Barrett Esophagus After Successful Elimination by Radiofrequency Ablation | NCT02521285 | Barrett Esophag... | Aspirin Laboratory Biom... Placebo Adminis... Questionnaire A... | 18 Years - 75 Years | National Cancer Institute (NCI) | |
| Culturally Adapted Mobile Treatment of Chronic Pain in Adolescent Survivors of Pediatric Bone Sarcoma | NCT05746429 | Bone Sarcoma | Cognitive Behav... Transcranial Di... Interview Placebo Adminis... Questionnaire A... | 10 Years - | St. Jude Children's Research Hospital | |
| Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery | NCT03317405 | Breast Ductal C... Breast Lobular ... Stage 0 Breast ... Stage I Breast ... Stage IA Breast... Stage IB Breast... Stage II Breast... Stage IIA Breas... Stage IIB Breas... Stage III Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... | Endoxifen Hydro... Placebo Adminis... Questionnaire A... | 18 Years - | National Cancer Institute (NCI) | |
| Curcumin in Preventing Gastric Cancer in Patients With Chronic Atrophic Gastritis or Gastric Intestinal Metaplasia | NCT02782949 | Chronic Atrophi... | Curcumin Laboratory Biom... Placebo Adminis... Quality-of-Life... | 21 Years - | National Cancer Institute (NCI) | |
| Fisetin to Improve Physical Function in Stage I-III Breast Cancer Survivors | NCT05595499 | Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... | Biospecimen Col... Fisetin Placebo Adminis... Quality-of-Life... Questionnaire A... | - | Jonsson Comprehensive Cancer Center | |
| Olanzapine for the Treatment of Chronic Nausea and/or Vomiting in Patients With Advanced Cancer | NCT05403580 | Advanced Malign... Hematopoietic a... | Olanzapine Placebo Adminis... Questionnaire A... | 18 Years - | Mayo Clinic | |
| Curcumin in Preventing Gastric Cancer in Patients With Chronic Atrophic Gastritis or Gastric Intestinal Metaplasia | NCT02782949 | Chronic Atrophi... | Curcumin Laboratory Biom... Placebo Adminis... Quality-of-Life... | 21 Years - | National Cancer Institute (NCI) | |
| Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery | NCT01386385 | Lung Adenocarci... Lung Adenocarci... Lung Large Cell... Lung Squamous C... Minimally Invas... Stage III Lung ... Stage IIIA Lung... Stage IIIB Lung... | 3-Dimensional C... Carboplatin Laboratory Biom... Paclitaxel Placebo Adminis... Veliparib | 18 Years - | National Cancer Institute (NCI) | |
| Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO Trial | NCT06022822 | Prostate Adenoc... | Biopsy Biospecimen Col... Placebo Adminis... Urolithin A Sup... | 18 Years - | National Cancer Institute (NCI) | |
| Simvastatin in Preventing Liver Cancer in Patients With Liver Cirrhosis | NCT02968810 | Cirrhosis Hepatocellular ... | Biospecimen Col... Computed Tomogr... Magnetic Resona... Placebo Adminis... Questionnaire A... Simvastatin | 18 Years - | National Cancer Institute (NCI) | |
| Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial) | NCT02194738 | Stage IB Lung N... Stage II Lung N... Stage IIA Lung ... Stage IIB Lung ... Stage IIIA Lung... Stage IIIA Lung... Stage IIIB Lung... | Biospecimen Col... Carboplatin Cisplatin Clinical Observ... Computed Tomogr... Crizotinib Cytology Specim... Echocardiograph... Erlotinib Gemcitabine Hyd... Nivolumab Paclitaxel Pembrolizumab Pemetrexed Pemetrexed Diso... Placebo Adminis... Positron Emissi... | 18 Years - | National Cancer Institute (NCI) | |
| Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma | NCT02443077 | Recurrent Diffu... Refractory Diff... | Autologous Bone... Autologous Hema... Carmustine Cyclophosphamid... Cytarabine Etoposide Ibrutinib Laboratory Biom... Melphalan Pharmacogenomic... Placebo Adminis... | 18 Years - | National Cancer Institute (NCI) | |
| Leflunomide for the Treatment of Severe COVID-19 in Patients With a Concurrent Malignancy | NCT04532372 | Hematopoietic a... Malignant Solid... Symptomatic COV... | Best Practice Leflunomide Placebo Adminis... | 18 Years - | City of Hope Medical Center | |
| Cognitive Behavioral Therapy and Multimodal Therapy in Treating Sleep Disturbance in Patients With Cancer | NCT01628029 | Hematopoietic a... Malignant Solid... Sleep Disorder | Counseling Methylphenidate... Phototherapy Placebo Adminis... Quality-of-Life... Sham Interventi... Therapeutic Mel... | 18 Years - | M.D. Anderson Cancer Center | |
| Iodine I-131 With or Without Selumetinib in Treating Patients With Recurrent or Metastatic Thyroid Cancer | NCT02393690 | Metastatic Thyr... Poorly Differen... Recurrent Thyro... Stage IV Thyroi... Stage IV Thyroi... Stage IVA Thyro... Stage IVA Thyro... Stage IVB Thyro... Stage IVB Thyro... Stage IVC Thyro... Stage IVC Thyro... | Iodine I-131 Placebo Adminis... Selumetinib | 18 Years - | Academic and Community Cancer Research United | |
| Testing the Effects of Oxybutynin for the Treatment of Hot Flashes in Men Receiving Hormone Therapy for Prostate Cancer | NCT04600336 | Prostate Carcin... | Oxybutynin Chlo... Placebo Adminis... Quality-of-Life... Questionnaire A... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Iloprost in Preventing Lung Cancer in Former Smokers | NCT02237183 | Lung Carcinoma | Iloprost Placebo Adminis... Quality-of-Life... Questionnaire A... | 18 Years - 85 Years | National Cancer Institute (NCI) | |
| Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With Paclitaxel (Phase II) | NCT05751668 | Anatomic Stage ... Chemotherapy-In... Metastatic Brea... | Paclitaxel Monosialotetrah... Questionnaire A... Quality-of-life... Placebo Adminis... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial) | NCT02193282 | Lung Non-Squamo... Stage IB Lung N... Stage II Lung N... Stage IIA Lung ... Stage IIB Lung ... Stage IIIA Lung... | Clinical Observ... Erlotinib Hydro... Laboratory Biom... Placebo Adminis... | 18 Years - | National Cancer Institute (NCI) | |
| Atorvastatin for Preventing Disease Metastasis in Patients With Resected High-Risk Stage IIA Melanoma | NCT06157099 | Clinical Stage ... | Atorvastatin Placebo Adminis... Computed Tomogr... Magnetic Resona... Electronic Heal... | 18 Years - | OHSU Knight Cancer Institute | |
| Ketoconazole in Treating Participants With Ongoing EGFR Inhibitor-Induced Rash | NCT03471364 | Malignant Neopl... | Ketoconazole Laboratory Biom... Placebo Adminis... Quality-of-Life... Questionnaire A... | 18 Years - | Mayo Clinic | |
| Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery | NCT01004978 | Hepatocellular ... Unresectable He... | Cisplatin Computed Tomogr... Doxorubicin Hyd... Doxorubicin-Elu... Laboratory Biom... Magnetic Resona... Mitomycin Pharmacological... Placebo Adminis... Sorafenib Tosyl... | 18 Years - | National Cancer Institute (NCI) | |
| PROSTVAC (PSA-TRICOM) in Preventing Disease Progression in Patients With Localized Prostate Cancer Undergoing Active Surveillance | NCT02326805 | Stage I Prostat... Stage II Prosta... | Laboratory Biom... Placebo Adminis... Rilimogene Galv... | - | National Cancer Institute (NCI) | |
| Aspirin in Preventing Colorectal Cancer in Patients With Colorectal Adenoma | NCT02965703 | Colorectal Aden... | Aspirin Biospecimen Col... Placebo Adminis... Questionnaire A... Rectal Biopsy | 18 Years - | National Cancer Institute (NCI) | |
| Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer | NCT03914612 | Endometrial Cle... Endometrial Ded... Endometrial End... Endometrial Mix... Endometrial Ser... Endometrial Und... Recurrent Endom... Recurrent Endom... Recurrent Endom... Recurrent Endom... Recurrent Endom... Recurrent Endom... Recurrent Endom... Recurrent Endom... Stage III Uteri... Stage IV Uterin... | Carboplatin Computed Tomogr... Paclitaxel Pembrolizumab Placebo Adminis... Quality-of-Life... Questionnaire A... | 18 Years - | National Cancer Institute (NCI) | |
| Phytocannabinoids for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors | NCT05672342 | Breast Carcinom... Chemotherapy-In... Colon Carcinoma | Cannabidiol Delta-8-Tetrahy... Placebo Adminis... Questionnaire A... | 18 Years - | City of Hope Medical Center | |
| T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial | NCT04457596 | Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... Anatomic Stage ... HER2 Positive B... Invasive Breast... Multifocal Brea... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Prognostic Stag... Synchronous Bil... | Trastuzumab Emt... Placebo Adminis... Tucatinib Questionnaire A... Quality-of-Life... | 18 Years - | Alliance for Clinical Trials in Oncology | |
| Phytocannabinoids for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors | NCT05672342 | Breast Carcinom... Chemotherapy-In... Colon Carcinoma | Cannabidiol Delta-8-Tetrahy... Placebo Adminis... Questionnaire A... | 18 Years - | City of Hope Medical Center | |
| APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Curative Intent Therapy in Patients With Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation | NCT04858334 | Pancreatic Acin... Pancreatic Aden... Pancreatic Squa... Resectable Panc... Resectable Panc... Resectable Panc... Resectable Panc... | Biospecimen Col... Computed Tomogr... Magnetic Resona... Olaparib Placebo Adminis... | 18 Years - | National Cancer Institute (NCI) | |
| Temozolomide With or Without Veliparib in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | NCT02152982 | Glioblastoma Gliosarcoma | Laboratory Biom... Placebo Adminis... Quality-of-Life... Temozolomide Veliparib | 18 Years - | National Cancer Institute (NCI) | |
| Alteplase Through an Indwelling Pleural Catheter for the Management of Symptomatic Septated Malignant Pleural Effusion | NCT06184321 | Hematopoietic a... Malignant Solid... | Alteplase Placebo Adminis... | 18 Years - | M.D. Anderson Cancer Center | |
| Nutrition Therapy in Improving Immune System in Patients With Bladder Cancer That Can Be Removed by Surgery | NCT03757949 | Bladder Carcino... | Laboratory Biom... Nutritional Int... Placebo Adminis... Quality-of-Life... Questionnaire A... | 18 Years - | SWOG Cancer Research Network | |
| Temozolomide and Radiation Therapy With or Without Cediranib Maleate in Treating Patients With Newly Diagnosed Glioblastoma | NCT01062425 | Adult Glioblast... Adult Gliosarco... | 3-Dimensional C... Cediranib Malea... Intensity-Modul... Laboratory Biom... Placebo Adminis... Temozolomide | 18 Years - | National Cancer Institute (NCI) | |
| Multi-epitope Folate Receptor Alpha Peptide Vaccine, GM-CSF, and Cyclophosphamide in Treating Patients With Triple Negative Breast Cancer | NCT03012100 | Bilateral Breas... Breast Inflamma... Stage IB Breast... Stage II Breast... Stage IIA Breas... Stage IIB Breas... Stage III Breas... Stage IIIA Brea... Stage IIIB Brea... Stage IIIC Brea... Triple-Negative... Unilateral Brea... | Cyclophosphamid... Laboratory Biom... Multi-epitope F... Placebo Adminis... Sargramostim | 18 Years - | Academic and Community Cancer Research United | |
| Bupropion to Reduce Cancer Related Fatigue in Cancer Survivors | NCT03996265 | Be Diagnosed Wi... | Bupropion Hydro... Placebo Adminis... Quality-of-Life... Questionnaire A... | 18 Years - | University of Rochester | |
| Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib Malate in Treating Patients With Extensive-Stage Small Cell Lung Cancer | NCT00453154 | Extensive Stage... Recurrent Lung ... | Carboplatin Cisplatin Etoposide Laboratory Biom... Placebo Adminis... Sunitinib Malat... | 18 Years - | National Cancer Institute (NCI) | |
| Dolcanatide in Preventing Colorectal Cancer in Healthy Volunteers | NCT03300570 | Colorectal Carc... | Dolcanatide Laboratory Biom... Placebo Adminis... Questionnaire A... | 18 Years - 65 Years | National Cancer Institute (NCI) | |
| CD24Fc for the Treatment of Immune Related Adverse Events in Patients With Advanced Solid Tumors, TIRAEC Study | NCT04552704 | Advanced Malign... | CD24 Extracellu... Placebo Adminis... | 18 Years - | University of California, Davis | |
| Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to Radiation Therapy for Localized Pancreatic Cancer | NCT04172532 | Locally Advance... Locally Advance... Stage II Pancre... Stage III Pancr... Unresectable Pa... | Biopsy Biospecimen Col... Computed Tomogr... Hypofractionate... Magnetic Resona... Peposertib Placebo Adminis... | 18 Years - | National Cancer Institute (NCI) | |
| Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant | NCT05457959 | Diffuse Hemisph... | Dendritic Cell ... Ipilimumab Leukapheresis Nivolumab Placebo Adminis... Placebo Adminis... Poly ICLC Resection | 13 Years - 60 Years | Jonsson Comprehensive Cancer Center | |
| Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma | NCT04201873 | Recurrent Gliob... | Dendritic Cell ... Pembrolizumab Placebo Adminis... Poly ICLC | 18 Years - | Jonsson Comprehensive Cancer Center | |
| Metformin in High Responder Polycystic Ovary Syndrome (PCOS) Patients Undergoing IVF Cycles | NCT01233206 | Infertility Polycystic Ovar... | Metformin Placebo adminis... | 18 Years - 35 Years | University Magna Graecia | |
| Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant | NCT00114101 | DS Stage I Mult... DS Stage II Mul... DS Stage III Mu... Refractory Mult... Smoldering Mult... | Autologous Hema... Laboratory Biom... Lenalidomide Melphalan Peripheral Bloo... Placebo Adminis... | 18 Years - 70 Years | National Cancer Institute (NCI) | |
| Testing Dabrafenib and Trametinib With or Without Hydroxychloroquine in Stage IIIC or IV BRAF V600E/K Melanoma | NCT04527549 | Clinical Stage ... Locally Advance... Pathologic Stag... Pathologic Stag... Unresectable Me... | Dabrafenib Mesy... Hydroxychloroqu... Placebo Adminis... Trametinib Dime... | 18 Years - | Eastern Cooperative Oncology Group | |
| Olanzapine for the Management of Cancer Associated Appetite Loss in Patients With Advanced and Incurable Solid Tumors | NCT05705492 | Advanced Malign... | Biospecimen Col... Computed Tomogr... Olanzapine Placebo Adminis... Questionnaire A... | 18 Years - | OHSU Knight Cancer Institute |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
